Skip to main content
Article thumbnail
Location of Repository

The biopsychosocial effects of restless legs syndrome (RLS)

By Philip M Becker

Abstract

The symptoms of restless legs syndrome (RLS) are associated with reductions in patients’ quality of life (QoL) and mental heath. Sleep disturbance, which is often the most troublesome symptom of RLS, may have a negative impact on patients’ daytime cognitive abilities. Research has established a relationship between the symptoms of RLS and mood symptoms, but causality is unclear. Some studies have indicated that the symptoms of RLS precede those of depression or anxiety, and others relate the severity of mood symptoms to the severity of RLS symptoms. Associations between the sleep disturbance produced by RLS and patients’ mood symptoms have also been demonstrated. The impact of RLS symptoms and their treatment on QoL, mental health, and cognition are reviewed herein

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2671952
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1999). A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.
    2. (1999). A randomized controlled study of pergolide in patients with restless legs syndrome.
    3. (2003). Acute double-blind, placebocontrolled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome.
    4. (2002). Acute placebocontrolled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci,
    5. (2004). An algorithm for the management of restless legs syndrome. Mayo Clin Proc,
    6. (2005). Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med,
    7. (2005). Anxietas tibiarum”. Depression and anxiety disorders in patients with restless legs syndrome.
    8. (2004). Augmentation and tolerance with longterm pramipexole treatment of restless legs syndrome (RLS). Sleep Med,
    9. (1996). Augmentation of the restless legs syndrome with carbidopa/levodopa.
    10. (2005). Bupropion may improve restless legs syndrome: a report of three cases.
    11. (2000). Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients.
    12. (1997). Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord,
    13. (2006). Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med,
    14. (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety,
    15. (2004). Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey.
    16. (1993). Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases.
    17. (2001). Dopaminergic neurotransmission and restless legs syndrome: a genetic association analysis.
    18. (2002). EEG mapping in patients with restless legs syndrome as compared with normal controls. Psychiatry Res,
    19. (2002). EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med,
    20. (1989). Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?
    21. (2000). Epidemiology of restless legs symptoms in adults.
    22. (2004). Evaluating the quality of life of patients with restless legs syndrome. Clin Ther,
    23. (2002). Evidence for a genetic association between monoamine oxidase A and restless legs syndrome.
    24. (1996). Fluoxetine and restless legs syndrome.
    25. (2004). Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail,
    26. (1996). Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls.
    27. (2005). Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome.
    28. (2004). Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS Epidemiology, Symptoms, and Treatment) Primary Care study. Sleep Med,
    29. (1995). L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial.
    30. (2004). Modeling the causal relationships between symptoms associated with restless legs syndrome and the patientreported impact of RLS. Sleep Med,
    31. (2003). Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome.
    32. (2004). Pergolide use in Parkinson disease is associated with cardiac valve regurgitation.
    33. (2004). Periodic limb movement disorder and restless legs syndrome in dialysis patients. Nephrology
    34. (2004). Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.
    35. (2003). Pramipexole in the management of restless legs syndrome: an extended study.
    36. (2000). Prevalence and risk factors of RLS in an elderly population. The MEMO study.
    37. (2001). Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord,
    38. (1999). Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial.
    39. (1998). Restless leg syndrome exacerbated by sertraline.
    40. (2001). Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebocontrolled sleep laboratory studies with clonazepam.
    41. (1996). Restless legs syndrome and paroxetine. Acta Psychiatr Scand,
    42. (2000). Restless legs syndrome in 218 patients: associated disorders. Sleep Med,
    43. (2002). Restless legs syndrome induced by mirtazapine.
    44. (2005). Restless legs syndrome prevalence and impact: REST general population study.
    45. (2002). Restless legs syndrome probably induced by risperidone treatment.
    46. (2005). Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant,
    47. (2005). Restless legs syndrome, periodic limb movements in sleep, and depression.
    48. (2001). Restless legs syndrome: a review of clinical and pathophysiologic features.
    49. (2003). Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med,
    50. (2006). Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc,
    51. (2004). Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.
    52. (2004). Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study.
    53. (1996). Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults.
    54. (2004). Symptoms of attention-deficit/ hyperactivity disorder in adults with restless legs syndrome.
    55. (2002). Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study.
    56. (2002). Valvular heart disease in patients taking pergolide. Mayo Clin

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.